Disease relevance of AGTR1

• The purpose of this study was to asses the effects of enalaprilat and L-158,809, an angiotensin II type-1 receptor antagonist, on LV diastolic function in 16 normal control dogs and 20 LVH dogs with perinephritic hypertension [1].
• Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade [1].
• Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs [2].
• Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion [3].
• Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy [4].

High impact information on AGTR1

• Using specific competitive PCR assays, we found that RVHF was associated with significant increases in RV mRNA levels of angiotensin converting enzyme and angiotensin II type 2 receptor, and with significant decreases of RV expression of chymase and the angiotensin II type 1 receptor, while RV angiotensinogen and renin remained unchanged [5].
• BACKGROUND: We previously reported that an AT1R antagonist, candesartan, prevents acute electrical remodeling in a rapid pacing model [6].
• The purpose of the present study was to evaluate the effect of angiotensin II type 1 receptor (AT1R) antagonist on chronic structural remodeling in atrial fibrillation (AF) [6].
• We have investigated the effects of the angiotensin II type 1 receptor antagonist candesartan, and the angiotensin II converting enzyme inhibitor ramipril, on catecholamine release from the anaesthetized dog's adrenal gland [7].
• The results indicate that angiotensin II potentiates sympathetic purinergic and adrenergic vasoconstrictions through the prejunctional angiotensin II type 1 receptor subtype in the canine splenic artery [8].

Chemical compound and disease context of AGTR1

• Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat [9].

Biological context of AGTR1

• Angiotensin II inhibition reduced leukocyte infiltration and improved left ventricular ejection fraction during reperfusion by angiotensin-converting enzyme inhibition or by angiotensin II type 1 receptor blocker [10].

Anatomical context of AGTR1

• Hemodynamic effects of valsartan ((S)-N-valeryl-N-¿[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]meth yl¿valine, CAS 137862-53-4, CGP 48933), a non-peptide angiotensin II type 1 receptor antagonist were examined in dogs with heart failure induced acutely by coronary artery ligation and chronically by rapid-ventricular pacing [11].

Associations of AGTR1 with chemical compounds

• We examined whether angiotensin converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor blockers (ARB) prevent isoproterenol (ISO)-induced left ventricular (LV) dysfunction in dogs [12].
• Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog [13].
• L-158,809 is a new angiotensin II type 1 receptor antagonist [14].
• Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs [15].
• Efficacy of pretreatment with the angiotensin II type 1 receptor blocker UP269-6 and losartan in the dog: effect on hemodynamics and ischemia-reperfusion [16].

Other interactions of AGTR1

• Angiotensin II type 1 receptor antagonist versus angiotensin I-converting enzyme inhibitor in experimental renal diseases [17].

Analytical, diagnostic and therapeutic context of AGTR1

• Several clinical trials have demonstrated that angiotensin-converting enzyme inhibitor (ACEI) and angiotensin II type 1 receptor blocker (ARB) are equally effective in the treatment of chronic heart failure [18].
• Molecular cloning and pharmacological characterization of an atypical gerbil angiotensin II type-1 receptor and its mRNA expression in brain and peripheral tissues [19].

References